Charles River Laboratories (CRL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2025 | 12-2024 | 09-2024 | 06-2024 | 03-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 229,356 | 194,606 | 210,171 | 179,213 | 327,039 |
| Receivables | 756,629 | 720,915 | 754,207 | 762,221 | 786,980 |
| Inventories | 290,156 | 278,544 | 336,200 | 349,111 | 361,281 |
| Other current assets | 100,230 | 105,796 | 101,514 | 110,836 | 99,054 |
| TOTAL | $1,506,358 | $1,403,071 | $1,494,723 | $1,499,273 | $1,668,188 |
| Non-Current Assets | |||||
| PPE Net | 1,587,069 | 1,604,014 | 1,639,978 | 1,613,895 | 1,618,708 |
| Investments And Advances | 214,026 | 218,350 | 235,987 | 231,859 | 243,543 |
| Intangibles | 3,529,107 | 3,570,008 | 3,903,053 | 3,879,822 | 3,897,879 |
| Other Non-Current Assets | 745,806 | 732,902 | 730,101 | 723,434 | 724,465 |
| TOTAL | $6,076,008 | $6,125,274 | $6,509,119 | $6,449,010 | $6,484,595 |
| Total Assets | $7,582,366 | $7,528,345 | $8,003,842 | $7,948,283 | $8,152,783 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 149,334 | 140,337 | 135,963 | 133,101 | 129,682 |
| Accrued Expenses | 439,792 | 411,428 | 419,201 | 368,823 | 380,498 |
| Other current liabilities | 211,467 | 194,014 | 205,089 | 198,418 | 188,247 |
| TOTAL | $1,051,055 | $994,101 | $1,012,221 | $947,519 | $954,810 |
| Non-Current Liabilities | |||||
| Long Term Debt | 2,510,754 | 2,240,205 | 2,326,653 | 2,409,380 | 2,660,459 |
| Deferred Revenues | 250,462 | 248,322 | 251,968 | 247,177 | 256,383 |
| Other Non-Current Liabilities | 712,761 | 720,059 | 709,078 | 698,702 | 709,748 |
| TOTAL | $3,331,192 | $3,067,292 | $3,204,494 | $3,273,746 | $3,551,823 |
| Total Liabilities | $4,382,247 | $4,061,393 | $4,216,715 | $4,221,265 | $4,506,633 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 49,116 | 51,142 | 51,136 | 51,631 | 51,512 |
| Common Shares | 512 | 511 | 517 | 517 | 515 |
| Retained earnings | 1,837,569 | 1,812,100 | 2,122,835 | 2,053,557 | 1,959,777 |
| Other shareholders' equity | -259,014 | -311,896 | -187,638 | -265,685 | -244,555 |
| TOTAL | $3,200,119 | $3,466,952 | $3,787,127 | $3,727,018 | $3,646,150 |
| Total Liabilities And Equity | $7,582,366 | $7,528,345 | $8,003,842 | $7,948,283 | $8,152,783 |